3-(Substituted amino)-1H-isoindoles

ABSTRACT

3-(Substituted or unsubstituted amino)-1H-isoindoles, prepared by condensing 3-alkoxy-1H-isoindoles or 3-(chloro or bromo)-1Hisoindoles with amine derivatives and optionally acylating the resulting 3-(primary or secondary amino)-1H-isoindoles or condensing the resulting 3-hydrazino-1H-isoindoles with an aldehyde or a ketone, are useful as antibacterial agents, as antihypertensive agents and/or as antiinflammatory agents.

United States Patent Diana Nov. 11, 1975 [54] B-(SUBSTITUTED AMlN())-lH-|S()1NDOLES 3.723i42l 3/1973 Diana 260 320 1 $753,994 8/l973 Diana 260/240 (i [75] lnventori Guy D. Diana, Stephentonn- NY.

[73] Assignee: Sterling Drug lnc.. New York, NY.

[22 Filed: Feb. 25, 1974 [2!] Appl. No: 445,645

Related US. Application Data [60] Division of Serv No 277.|52. Aug. 2. 1972. Pat No. 3.839.356. \\hieh is a continuation-in-purl oi Ser Nov 62.7lll. Aug l0. 197l| Pat No. 3.723.421v

[30] Foreign Application Priority Data Aug, 6. I971 Canada .7 |2003l [52] US. Cl. 260/240 F; 260/240 G; 260/325; 260/326.1; 260/566 A; 424/274 [5 [1 Int. Cl."' C07D 209/44 (58] Field of Search 260/240 G, 3261. 240 F [56] References Cited UNITED STATES PATENTS 3.345.355 l0/l967 Raue. 260/240 O OTHER PUBLICATIONS Eberle et all Chem. Abstracts 73 (1970) No 7717/v Primm v E.\(lIH/HI'-Aflhllf P. Demers Arm/Hey. Agent or FirmTheodore C. Miller; B, Woodrow Wyatt [5 7] ABSTRACT 3-(Substituted or unsubstituted amin0)-lH'isoindoles. prepared by condensing 3-alkoxy-lH-isoindoles or 3- (chloro or br0m0)-lH-isoindoles with amine derivatives and optionally acylating the resulting 3-(primury or secondary amino)-lH-is0indoles or condensing the resulting 3-hydrazino-lH-isoindoles with an aldehyde or a ketone. are useful as antibacterial agents. as anti hypertensive agents and/or as untiinflammator agents.

9 Claims. N0 Drawings S-(SUBSTITUTED AMINO )-lH-lSOlNDOLES (Formula I),

wherein X, when taken alone, is hydrogen, atertiary alkyl or one to four carbon atoms, phenyl, or phenylalkyl of seven to ten carbon atoms;

X, when taken alone, is hydrogen;

Y is N or NHN=CRR",

wherein:

0, when taken alone, is phenylalkyl of seven to ten carbon atoms; (CH ),,-T, wherein n is two or three and T is dialkylamino, wherein alkyl of dialkylamino is atertiary alkyl of one to four carbon atoms; amino or hydroxy;

0, when taken alone, is hydrogen or atertiary alkyl of one to four carbon atoms;

Q and 0', when taken together with N, are l-azacycloalkyl of five to seven ring atoms and four to ten carbon atoms;

R, when taken alone, is hydrogen, alkyl of one to six carbon atoms, alkenyl of two to six carbon atoms, cycloalkyl of three to seven ring atoms and three to ten carbon atoms, cycloalkenyl of five to seven ring atoms and five to ten carbon atoms, phenyl, phenylalkyl of seven to ten carbon atoms or phenylalkenyl of eight to twelve carbon atoms;

R', when taken alone, is hydrogen or atertiary alkyl of one to four carbon atoms;

R and R, when taken together with C, are cycloalkylidene of five to seven ring atoms and five to ten carbon atoms;

Z and Z, when taken alone, are the same or different and are hydrogen, atertiary alkyl of one to four carbon atoms, halo, hydroxy or atertiary alkoxy of one to four carbon atoms;

Z and Z, when taken together, are methylenedioxy;

and wherein,

when 0 is phenylalkyl or when R is phenyl, phenylalkyl or phenylalkenyl, the benzene ring thereof can be substituted by one to three members selected from the group consisting of halo, hydroxy, atertiary alkyl of one to four carbon atoms, atertiary alkoxy of one to four carbon atoms and phenylalkoxy of seven to ten carbon atoms or by a member selected from the group consisting of atertiary alkylthio of one to four carbon atoms, dialkylamino and B-dialkylaminoethoxy, wherein alkyl or dialkyl- 2 amino is atertiary alkyl of one to four carbon atoms, nitro and sulfamoyl;

and acid addition salts thereof.

In its other composition of matter aspect my invention provides l-(X)-l-(X')-3-(Y)-5-(Z)-6-(Z)-ll-lisoindole of Formula I wherein X and X, when taken together, are benzylidene, a-chlorobenzylidene, or abromobenzylidene; I

wherein Q", when taken alone is hydrogen; alkyl of one to six carbon atoms; phenylalkyl of seven to ten carbon atoms; (CH ),,-T, wherein n is two or three and T is dialkylamino, wherein alkyl of dialkylamino is atertiary alkyl of one to four carbon atoms; amino or hydroxy;

0', when taken alone, is hydrogen or atertiary alkyl of one to four carbon atoms;

0" and Q, when taken together with N, are l-azacycloalkyl of five to seven ring atoms and four to ten carbon atoms;

R, when taken alone, is hydrogen, alkyl of one to six carbon atoms, alkenyl of two to six carbon atoms, cycloalkyl of three to seven ring atoms and three to ten carbon atoms, cycloalkenyl of five to seven ring atoms and five to ten carbon atoms, phenyl, phenylalkyl of seven to ten carbon atoms or phenylalkenyl of eight to twelve carbon atoms;

R, when taken alone, is hydrogen or atertiary alkyl of one to four carbon atoms;

R and R, when taken together with C, are cycloalkylidene of five to seven ring atoms and five to ten carbon atoms;

Z and 2', when taken alone, are the same or different and are hydrogen, atertiary alkyl of one to four carbon atoms, halo, hydroxy or atertiary alkoxy of one to four carbon atoms;

Z and Z, when together, are methylenedioxy; and

wherein, when Q" is phenylalkyl or when R is phenyl, phenylalkyl or phenylalkenyl, the benzene ring thereof can be substituted by one to three members selected from the group consisting of halo, hydroxy, atertiary alkyl of one to four carbon atoms, atertiary alkoxy of one to four carbon atoms and phenylalkoxy of seven to ten carbon atoms or by a member selected from the group consisting of atertiary alkylthio of one to four carbon atoms, dialkylamino and B- dialkylaminoethoxy, wherein alkyl of dialkylamino is atertiary alkyl of one to four carbon atoms, nitro and sulfamoyl;

and acid addition salts thereof.

The isoindoles of Formula I and acid addition salts thereof have antibacterial activity, antihypertensive activity and/or antiinflammatory activity and are useful as antibacterial agents, as antihypertensive agents and/or as antiinflammatory agents.

In the first of its process aspects my invention provides the process for producing l'(X")-l -(X)-3-(Y)- 5-(Z)-6-(Z')-lH-isoindole of the formula (Formula II),

3 wherein X", when taken alone, is hydrogen, atertiary alkyl of one to four carbon atoms, phenyl, or phenylalkyl of seven to ten carbon atoms;

X, when taken alone, is hydrogen as recited above for Formula I;

wherein 0, when taken alone, is phenylalkyl of seven to ten carbon atoms unsubstituted or substituted in the benzene ring as recited above for Formula I; (Cl-l ),,-T. wherein n is two or three and T is dialkylamino, wherein alkyl of dialkylamino is atertiary alkyl of one to four carbon atoms; amino or hydroxy as recited above for Formula I;

Q, when taken alone, is hydrogen or atertiary alkyl of one to four carbon atoms as recited above for Formula I;

Q and Q, when taken together with N, are l-azacycloalkyl of five to seven ring atoms and four to ten carbon atoms as recited above for Formula I;

Z and Z are defined as recited above for Formula I; which comprises the step of condensing l-(X")-l- (X)-3-(OQ'")-5-(Z)-6-(Z')-lH-isoinclole of the formula l xl (Formula III), 2

AQI"

wherein Q' is methyl. ethyl or propyl, with an amine, a hydrazine or a hydroxylamine of the formula HNQQ' or an acid addition salt thereof.

In the second of its process aspects my invention provides the process for producing l-(X")-l-(X')-3-(Y)- 5-(Z)-6-(Z')-lH-isoindole of Formula II wherein:

X" and X, when taken together, are benzylidene;

Y is NO"Q'; wherein 0'. when taken alone, is hydrogen, alkyl of one to six carbon atoms; phenylalkyl of seven to ten carbon atoms unsubstituted or substituted in the benzene ring as recited above in Formula I; (CH,),,-T, wherein n is two or three and T is dialkylamino, wherein alkyl of dialkylamino is atertiary alkyl of one to four carbon atoms; amino or hydroxy as recited above for Formula I;

Q, when taken alone, is hydrogen or atertiary alkyl of one to four carbon atoms as recited above for Formula I;

Q" and 0, when taken together with N, are l-azacycloalkyl of five to seven ring atoms and four to ten carbon atoms;

Z and Z are defined as recited above for Formula I;

which comprises the step of condensing l-(X")-l- (X')-3-(OQ"')-5-(Z)-6-(Z')-1H-isoindole of the Q is methyl, ethyl or propyl, with an amine, a hydrazine or a hydroxylamine of the formula HNQA 'Q' or an acid addition salt thereof.

In the third of its process aspects my invention provides the process for producing l-(X"',X""- methylene)-3-(NQ"Q')-5-(Z)-6-(Z')-lH-isoindole of the formula XIII N (Formula Iv),

wherein:

X' is phenyl X"" is chloro or bromo;

Q" and Q are defined as recited above for Formula Z and Z are defined as recited above for Formula I;

which comprises the steps of chlorinating or brominating 3-(X"'-methylene)-5-(Z)-6-(Z')-phthalimidine of the formula (Formula V),

and condensing the resulting l-(X"',X""-methylene)- 3-(X"")5-(Z)-6-(Z')-ll-l-isoindole of the formula i z no (Formula VI) (Formula VII),

wherein X", X, R, R, Z and Z are defined as recited above for Formulas l and ll, which comprises the step of condensing l-(X)-l-(X)-5-(Z)6-(Z")-3-hydrazinolH-isoindole of the formula (Formula NIII),

or an acid addition salt thereof with an aldehyde or a ketone of the formula O=CRR'.

Throughout this specification a symbol used in one formula has the same meaning when used in any other formula.

in the definitions of the formulas above atertiary alkyl of one to four carbon atoms is methyl. ethyl, propyl, isopropyl, butyl, isobutyl or sec-butyl. Atertiary alkoxy of one to four carbon atoms is methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy or sec-butoxy. Atertiary alkylthio of one to four carbon atoms is methylthio, ethylthio, propylthio, isopropylthio. butylthio, isobutylthio or sec-butylthio.

When X, X", 0, Q" or R is phenylalkyl of seven to ten carbon atoms, phenylalkyl is, for example, benzyl, l-phenylethyl, 3-phenylpropyl or I -methyl-1- phenylethyl.

When 0" or R is alkyl of one to six carbon atoms, alkyl can be branched or unbranched alkyl, as illustrated by methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl.

When 0 and Q, or Q" and Q taken together with N, are l-azacycloalkyl of five to seven ring atoms and four to ten carbon atoms, l-azacycloalkyl can be branched or unbranched l-azacycloalkyl, as illustrated by l-pyrrolidinyl, piperidino, 4-methyl-l-piperidinyl and l-hexahydroazepinyl.

When R is alkenyl of two to six carbon atoms, alkenyl can be branched or unbranched alkenyl, as illustrated by vinyl, allyl, l-methyl-l-propenyl and 2-hexenyl.

When R is cycloalkyl of three to seven ring atoms and three to ten carbon atoms, cycloalkyl can be branched or unbranched cycloalkyl, as illustrated by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-methylcyclohexyl and cycloheptyl.

When R is cycloalkenyl of five to seven ring atoms and five to ten carbon atoms, cycloalkenyl can be branched or unbranched cycloalkenyl, as illustrated by l-cyclopentenyl, 3-cyclohexenyl, 4-methyl-3- cyclohexenyl and l-cycloheptenyl.

When R is phenylalkenyl of eight to twelve carbon atoms, phenylalkenyl is, for example, styryl, a-methylstyryl or B-methylstyryl.

When R and R, taken together with C, are cycloalkylidene of five to seven ring atoms and five to ten carbon atoms, cycloalkylidene can be branched or unbranched cycloalkylidene, as illustrated by cyclopentylidene, cyclohexylidene, 4-methylcyclohexylidene and cycloheptylidene.

As benzene ring substituents halo is fluoro, chloro, bromo or iodo and phenylalkoxy is illustrated by benzyloxy, B-phenylethoxy and B-phenylpropoxy.

The manner and process of making and using the invention and the best mode of carrying it out will now be described so as to enable any person skilled in the art to which it pertains to make and use it.

Condensation of l-(X")-l-(X')-3-(OQ'")-5-(Z)-6- (Z')-lH-isoindole of Formula III with an amine, a hydrazine or a hydroxylamine of the formula HNQQ' or HNQ"Q' or an acid addition salt thereof is performed with or without a diluent at a temperature in the range of 0l50C. If a diluent is used, it can be any solvent inert under the reaction conditions, for example, methanol, ethanol, Z-propanol, acetonitrile, dimethylsulfoxide, N,N-dimethylformamide or mixtures thereof.

Chlorination or bromination of l-(X"-rnethylene)- S-(Z)-6-(Z')-phthalimidine of Formula V is accom- 7 plished using a chlorinating or brominating agent, preferably thionyl chloride or thionyl bromide, with or without a diluent at a temperature in the range of -l 50C. lfa diluent is used, it can be any solvent inert under the reaction conditions, for example, chloroform, benzene or chlorobenzene.

Condensation of l-(X"', X""-methylene)-3-(X"")- 5-(Z)-6-(Z')-lH-isoindole of Formula VI with an amine. a hydrazine or a hydroxylamine of the formula HNQQ' is carried out using a solvent inert under the reaction conditions at a temperature in the range of lS0C. Ether is the preferred solvent, although tetrahydrofuran, chloroform, benzene or dioxane or mixtures thereof can also be used.

Condensation of l-(X)-l-(X)-(Z)-6-(Z)-3- hydrazino-IH-isoindole of Formula VIII or an acid addition salt thereof with an aldehyde or a ketone of the formula O=CRR' is effected with or without a diluent at a temperature in the range of 0l50C. If a diluent is used it can be any solvent inert under the reaction conditions, for example, methanol, ethanol, ether, benzene, tetrahydrofuran or mixtures thereof.

Acid addition salts of the isoindoles of Formula I of my invention can be prepared with any pharmaceutically acceptable inorganic (mineral) or organic acid. lf inorganic, the acid can be, for example, hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, or sulfamic acid. If organic, the acid can be, for example, acetic acid, glycolic acid, lactic acid, quinic acid, hydrocinnamic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid, benzenesulfonic acid, cyclohexanesulfamic acid or picric acid.

For the pharmaceutical purposes of this invention the free base forms of the isoindoles of Formula I and their corresponding acid addition salts are considered to be equivalent. That the protonic acid be pharmaceutically acceptable means that the beneficial properties inherent in the free base not be vitiated by side effects ascribable to the anions.

Although pharmaceutically acceptable salts are preferred, all acid addition salts are within the scope of the invention. A pharmaceutically unacceptable salt may be useful, for example, for purposes of identification or purification or in preparing a pharmaceutically acceptable salt by ion exchange procedures.

When crystalline, the isoindoles of Formulas l-Vlll and their acid addition salts are purified by recrystallization and are characterized by their melting points (m.p.). When liquid, the isoindoles of Formulas IVIIl are purified by distillation under reduced pressure and are characterized by their boiling points (b.p./mm.l'lg.). The structures of the isoindoles of Formula I follow from the route of synthesis and are corroborated by infrared spectral analysis, by nuclear magnetic resonance spectral analysis and by the correspondence of calculated and found values of elemental analysis of representative samples.

As stated above isoindoles of Formula I have antibacterial activity. This activity was measured by two test methods.

The first method is the spot plate test, which involves placing a few crystals of the compound to be tested on a seeded agar plate, incubating the plate and examining the plate for zones of inhibition of bacterial growth. A compound producing a zone of inhibition is recorded as active and a compound producing no zone of inhibition as inactive.

The second method is the broth dilution test by the Autotiter method. To the first cup of the Autotray is added an aliquot (0.08 ml.) of an aqueous solution I000 mcg./ml.) of the compound to be tested. Activation of the Autotiter initiates a sequence of operations in which an aliquot (0.05 ml.) of the solution in the first cup is withdrawn by a Microtiter transfer loop and diluted in sterile tryptose phosphate broth (0.05 ml.) in the second cup. Inoculated tryptose phosphate broth (0.05 ml.) containing triphenyltetrazolium chloride (50 mcg./ml.) as an indicator is then automatically added. After the initial dilution, the dilutions continue in twofold decrements (from 250 to 0.06 mcg./ml.). The Autotray is incubated l 8-20 hr. at 37C.) and the minimum inhibitory concentration determined as the concentration which inhibits formation of a red precipitate of the indicator. The isoindoles of Formula I had minimum inhibitory concentrations in the range of l5-250 micrograms per milliliter in this test.

In a modification of the foregoing broth dilution test the initial aliquot is different (0.1 mcg./ml. instead of 0.08 mcg./ml.), the broth contains glucose instead of tryptose phosphate, no indicator is used, the dilution range is different (from 500 to 0.06 mcg./ml. instead of 250 to 0.06 meg/ml.) and inhibition is judged by turbidity instead of by the appearance of a red precipitate.

The organisms used in the two broth dilution tests were Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Proteus vulgaris.

As stated above isoindoles of Formula I also have antihypertensive activity, which was tested by two methods.

In the first method the renal hypertensive rat is used. The compound to be tested is administered, preferably in the form of a pharmaceutically acceptable acid addition salt, orally as a gum tragacanth suspension or subcutaneously as an aqueous solution to three renal hypertensive rats at each of four different dose levels graduated at 0.3 to 0.9 logarithmic intervals. The systolic blood pressure is determined for each of the three rats at each dose level before medication and at intervals of 1, 2, 4, 5, 24 and 48 hours afier medication. The unmedicated rats are considered hypertensive if the systolic blood pressure is I60 millimeters of mercury or greater. The medicated rats are considered normotensive if the systolic blood pressure is millimeters of mercury or less. Each blood pressure reading is judged by these criteria. The dose level of test compound which reduces the systolic blood pressure to a normotensive level in 50% of the animals is defined as the AED (approximate effective dose) value. When tested in this way, isoindoles of Formula I were found to have AED values in the range of 5-50 milligrams per kilogram.

In the second method for testing antihypertensive activity the renal hypertensive rat or the spontaneous hypertensive [Okamoto and Ooki, Japan Circulation J., 27, 282( 1963)] rat is used. The compound to be tested is administered, preferably in the form of a pharmaceutically acceptable acid addition salt, orally as a gum tragacanth suspension or subcutaneously as an aqueous solution at one or more dose levels to five hypertensive rats at each dose level. The systolic blood pressure of each rat is determined before medication and at 2, 6 and 24 hours after medication. Of the values of the systolic blood pressure of each rat determined at 2, 6 and 24 hours which are lower than the premedication value, the lowest value is chosen. The difference between the premedication value and the lowest value is the maximum lowering of the systolic blood pressure and the maximum lowerings are averaged for each group of rats. When the data permit, at least three such average maximum lowerings are plotted to determine the Al-lD (antihypertensive dose) value, that is, the dose which would effect an average maximum lowering of 40 millimeters of mercury.

As further stated above isoindoles of Formula I have antiinflammatory activity. This activity was measured by two test methods.

The first method is the carrageenin edema method and is essentially that of VanArman, Begany, Miller and Pless, Journal of Pharmacology and Experimental Therapeutics 150, 328(1965) as modified by Winter, Risley and Nuss, Proceedings of the Society for Experimental Biology and Medicine 111, 544(1962). Young male rats weighing ll 10 grams are used. Food is withdrawn approximately 18 hours prior to medication, but the animals are permitted free access to drinking water up to the time of medication. Compounds to be tested are suspended by triturating in 1% gum tragacanth and administered by gavage in a volume of 1 milliliter per 100 grams of body weight. Control animals receive the gum tragacanth only. One hour after medication, 0.05 milliliter ofa 1% suspension of carrageenin in 0.9% saline is injected into the plantar tissue of the left hind paw. Three hours after injection of the carrageenin, edema formation, that is, increase in foot volume (difference between left hind paw and the uninjected right hind paw) is measured plethysmograpl'iically in the unanesthetized rat. The extended paw is immersed to the top of the most proximal callus pad into a mercury-filled glass cylinder connected to a pressure transducer and the impulse amplified and recorded by a polygraph. The polygraph is standardized for each assay so that a deflection of 3.6 millimeters on the recording paper is equivalent to a volume of 0.l milliliter. The results are expressed as percent inhibition calculated from the average differences in foot volume between the control and medicated rats. A compound is judged to be active if the differences in edema formation between medicated and control rats are statisti cally significant at the 5% level of probability. lsoindoles of Formula I were found to be active in this test at doses in the range of 50-300 milligrams per kilogram.

The second method is the adjuvant induced arthritis method and is a modification of the methods of Pearson, Journal of Chronic Diseases 16, 863(1963) and Glenn and Gray, American Journal of Veterinary Research 26, 1180(1965). Adult male rats weighing 200-230 grams are used. Adjuvant (M. butyricum, 0.1 milliliter of a 0.6% suspension in heavy mineral oil) is injected into the plantar tissue of the left hind paw. A negative control group is injected with mineral oil only. Beginning on the ninth day after adjuvant injection (polyarthritis does not appear until approximately the tenth day after adjuvant administration), the animals receive 6 daily medications of test compound suspended in 1% gum tragacanth and administered by gavage in a volume of 1 milliliter per 100 grams of body weight. Both the negative control and adjuvant injected control animals receive the vehicle only. Food and water are permitted ad libitum. Twenty-four hours after the last medication, the animals are weighed, the degree of arthritic involvement, that is, increase in foot volume (difference between adjuvant injected left hind paw and uninjected right hind paw) and plasma inflammation units are determined. Foot volume is measured plethysmographically in the unanesthetized rat. The extended paw is immersed to the top of the most proximal callus pad into a mercury-filled glass cylinder connected to a pressure tranducer and the impulse amplified and recorded by a polygraph. The polygraph is standardized for each assay so that a deflection of 3.6 millimeters on the recording paper is equivalent to a volume of 0.1 milliliter. The results are expressed as percent inhibition calculated from the average differences in foot volume between the adjuvant injected control and medicated rats correcting for difference in foot volume of the oil injected negative control group. Following foot volume measurements, the animals are etherized and bled by heart puncture into rubber stoppered evacuated glass tubes (calibrated to draw 2.7 milliliters) containing 0.3 milliliter of 0.1 M sodium oxalate solution for determination of plasma inflammation units. The unclotted blood is centrifuged and 0.1 milliliter of the plasma is diluted with 5.0 milliliter of 0.9% sodium chloride solution. The plasma inflammation units are direct spectrophotometer optical density readings expressed as the difference between preheated and heated (30 minutes at 56C.) plasma, corrected for 1:50 dilution. The results are expressed as percent inhibition calculated from the difference between the average plasma inflammation units of oil injected negative control rats. A compound is judged to be active if the differences between medicated and adjuvant injected controls are statistically significant at the 5% level of probability. lsoindoles of Formula I were found to be active in this test at doses in the range of 50-300 milligrams per kilogram.

The preparation of the intermediates of Formulas Ill and V will now be described.

Alkylation of 3-(X")-3-(X')-5-(Z')-6-(Z)-phthalimidine of the formula NH (Formula IX) 2 with a (Q"') O+(trialkyloxonium) salt provides 1- (X'A')-1-(X')-3-(OQ"')-5(Z)-6-(Z')-lH-isoindole of Formula 111. The preferred trialkyloxonium salt is tn'ethyloxonium fluoborate [(CzH O+BF Those phthalimidines of Formula l)( in which X" and X are hydrogen are prepared, for example, by zinc and acetic acid reduction of the corresponding phthalimides.

Those phthalimidines of Formula lX in which X" is alkyl, phenyl or phenylalkyl are prepared, for example, from the corresponding 3-(Z')-4-(Z)-phenyl-(X")- ketoximes of the formula (For-lull X) by treatment with carbon monoxide and hydrogen under pressure and catalysis by cobalt octacarbonyl. Those phthalimidines of Formula lX in which X is benzyl are also prepared by catalytic hydrogenation of the corresponding phthalimidines of Formula [X in which X and X. taken together. are benzylidene.

Those phthalimidines of Formula IX in which X and X, taken together, are benzylidene are the phthalimidines defined by Formula V and are prepared, for ex ample. by condensing phthalic anhydride with the corresponding a-(X"')-acetic acids under sodium acetate catalysis and treating the resulting 3-(X'-methylene)- 5-(Z')-6-(Z)-phthalides successively with sodium hydroxide, hydrochloric acid and ammonia.

The following examples illustrate specific embodiments of my invention without limiting the latter thereto.

EXAMPLE I A mixture of3-ethoxy-1H-isoindole (lll: X" X =Z Z H,Q C H,) fluoborate (17.5 g.), B-(dimethylamino)-ethylamine (25 ml.) and methylene dichloride was stirred at room temperature (for 3 da.), allowed to stand in the refrigerator (for 1 wk.), basified with cooling with potassium carbonate solution (50%, 30 ml). dried over magnesium sulfate and filtered. The filtrate was concentrated. A mixture of the resulting oil and ether (300 ml.) was acidified with ethereal hydrochloric acid. Two recrystallizations of the resulting solid from isopropyl alcohol afforded 3-{ [2-(dimethylamino)-ethyl]amino}-l l-I-isoindole (lzX X'= Z Z H, Y NQQ'. Q CH CH N(CH3)=. Q H) dihydrochloride (4.5 g., m.p. 258-260C. with decomposition).

EXAMPLE 2 Condensation of I -methyl-3-ethoxyl H-isoindole (Ill: X" CH X Z Z H, =C H,) and B- (dimcthylamino)ethylamine affords l-methyl-3{[2- (dimethylamino)ethylI-amino-llH-isoindole(l: X CH ,X'=Z=Z=H.Y=NQQ',Q= CH,CH N(CH Q H)- EXAMPLE3 Condensation of lethyl-3-ethoxy-lI-l-isoindole (Ill: X" Q'" C H X'= Z Z H) and B (dime thylamino)ethylamine afi'ords l-ethyl-3{[2 (dimethylamino)ethyl]amino}-IH-isoindole (I:X= C H X Z Z H, Y NQQ', Q CH,CH,N(CH Q H).

EXAMPLE 4 Condensation of l-isopropyl-3-ethoxy-lH-isoindole (Ill: X CH(CH X Z Z H, 0 C H 12 and B(dimethylamino)ethylamine affords I-isopropyl- 3-{[Z-(dimethylamino)ethyl]amino}-1H-isoindole (I:X CH(CH X Z Z H. Y NQQ', Q CH CH N(CH Q H).

EXAMPLE 5 Condensation of l-butyl-3-ethoxy-lH-isoindole (Ill: X" (CH CH X Z Z' H, 0 C H and B-(dimethylamino)-ethylamine affords Ibutyl-3-{[2- (dimethylamino)ethyl]amino}-lH-isoindole (l:X (CH CH X Z Z H, Y NQQ'. Q CH CH2N(CH3)2 Q, H)-

EXAMPLE 6 A mixture of l-phenyl-S-ethoxy-lH-isoindole (Ill: X" =C H X 2 2 H, 0 =C H,,) (14 g., m.p. 1 18l 20C.) and B-(dimethylamino)ethylamine (20 ml.) was heated under reflux (for 12 hr.). Part 1 1.5 g.) of the crystalline solid (l4.3 g.) which separated after cooling the mixture was dissolved in absolute ethanol 140 ml.) and treated with a solution of cyclohexanesulfamic acid (23.2 g.) in absolute ethanol ml.). The resulting solid was recrystallized from isopropyl alcohol-ether, affording l-phenyl-3-{[ Z-(dimethylamino)ethyl]amino}-H-isoindole (I:X=C6H X Z Z H, Y NQQ, Q CH CH N-(CH h, Q H) tris(cyclohexanesulfamate) (8.4 g., m.p. 152-l54C.).

EXAMPLE 7 In a manner similar to that of Example 6, condensation of l-benzyl-3-ethoxy-lI-I-isoindole (III: X CH C H X =2 =Z H, 0'' =C,H (17.3 g.) and B-(dimethylamino)ethylamine and treatment of an ethanol (300 ml.) solution of the resulting gum with picric acid (30 g. afforded l -benzyl-3-{[ 2-(dimethylamino)- ethyl]amino}-1H-isoindole (I:X= CH C H X Z Z H, Y N00, 0 CH CH N(CHa), Q =H) dipicrate (16.9 g., m.p. I96-I97C.).

Treatment of l-benzyl-{3[Z-(dimethylamino)ethyl]- amino}--l l-I-isoindole with cyclohexanesulfamic acid afforded l -benzyl-3 -{[2-(dimethylamino)ethyllamino} I H-isoindole tris( cyclohexanesulfamate) (m.p. l46-l48C.).

EXAMPLE 8 Condensation of l-(l-phenylethyl)-3-ethoxy-1H- EXAMPLE 9 In a manner similar to that of Example 1 condensation of l-benzylidene-3-ethoxy-l H-isoindole (III: X'k +X' CHC l-l Q C l-I Z Z H) (24.9 g., m.p. l02l05C.) and B-(dimethylamino)ethylamine (40 ml.) and treatment of the resulting product with hydrochloric acid afforded I-benzylidene-3-{[2-(dimethylamino)ethyl]amino}-II-I-isoindole (I: X+X' CHC H Y N00. 0 CH,CI-[,N(CH Q H, Z Z H) dihydrochloride (I6.0 g., m.p. 24024I C.).

EXAMPLE 10 A. A mixture of 2-benzylidenephthalimidine (V: X' C l-l Z Z H) (72 g.) and thionyl chloride (300 ml.) was heated under reflux (for 2 da.), then stripped CHC H Y NQ"Q', Q" I drochloride.

of excess thionyl chloride. The residue was digested with Skellysolve A (82.6 g., m.p. 122l23C.). Part (35 g.) of the digested residue was recrystallized from Skellysolve B and part (1 g.) of the recrystallizatewas again recrystallized from Skellysolve B, affording l-(achlorobenzylidene )-3-chloro-1H-isoindo1e (V1: X' C H X"" Cl, Z Z H) (0.7 g., m.p. 126-l28C.).

B. A mixture of 1-(a chlorobenzylidene)-3-chlorolH-isoindole (32.8 g.), B-(dimethylamino)ethylamine (21.1 g.) and ether (350 ml.) was stirred at room temperature (for 1.5 hr.) and filtered. Evaporation of the ether from the filtrate gave a viscous oil (40.1 g.), an ethereal solution of which was treated with hydrochloric acid. Two recrystallizations of the resulting solid (34.0 g., m.p. 159160C.) from isopropyl alcohol afforded 1 a-chlorobcnzylidene)-3-{ [2 -dimethylamino)-ethyl]amino}-1H-isoindole (I: X+X' CClC 1-1 Y NQ"Q', O"= CH CH,N(CH Q Z Z H) dihydrochloride (12.0 g., m.p. 272-273C. with decomposition).

EXAMPLE 11 By substituting thionyl bromide for thionyl chloride in Step A of Example and carrying the resulting 1- (a-bromobenzylidene)-3-bromo-1H-isoindole through Step B, 1-a-bromobenzylidene)-3-{[2-(dimethylamino)-ethyl]amino}-l H-isoindole (l: X X CBrC,]-1 Y NQ"Q, Q CH,Cl-1,N(CH;,),, Q Z Z H) dihydrochloride is obtained.

EXAMPLE 12 A mixture of 1-benzylidene-3-ethoxy-ll-l-isoindole (20.0 g.) and piperidine (40 ml.) was heated under reflux (for 14 hr.). The resulting mixture was digested with methanol and filtered. Recrystallization of the solid (18.3 g., m.p. l45-147C.) from Skellysolve B afforded 1-benzy1idene-3-piperidino-lH-isoindole (l: X+X CHC H Y NQ"O' l l(CH ),CH Z Z' H) (16.5 g., m.p. 145-l47C.).

EXAMPLE 13 A mixture of l-(a-chlorobenzylidene)-3-chloro-1l-lisoindole (22 g.), piper idine (13.6 g.) and ether (400 ml.) was stirred at room temperature (for 3 hr.). The mixture was filtered. The filtrate was dried and concentrated. Crystallization of the residue from Skellysolve A gave l-(a-chlorobenzy1idene)-3-piperidino-1H-isoindole (l: X+X' CClCH Y NQ"Q' IQ(CH,) CH,, Z =Z' H) (17.6 g., m.p. 62-63C.).

EXAMPLE 14 A mixture of 1-benzylidene-3-ethoxy-1H-isoindole (50 g.), ammonium chloride (20 g.) and methanol (1000 ml.) was heated under reflux (for 2.5 da.). Evaporation of the methanol and recrystallization of the residue, first from ethanol and then from isopropyl alcohol, gave 1-benzy1idene-3-amino-lH-isoindole (1: X+X' CHC,H,,, Y NQ"Q', Q Q Z Z H) hydrochloride (12.0 g., m.p. 256-257C. with decomposition).

EXAMPLE 15 Condensation of 1-benzylidene-3-ethoxy-1H-isoindole and methylammonium chloride affords l-benzylidene-3-(methylamino)-lH-isoindole (1: X+X' CH ,Q'=Z=Z'=H) hy- 14 EXAMPLE 16 Condensation of 1-benzylidene-3-ethoxy-1H-isoindole and isopropylammonium chloride affords l-benzylidene-3-(isopropylamino)-lH-isoindole (1: X+X' CHC H Y NQ"Q'. Q" CH(CHa)z. Q Z =Z' H) hydrochloride.

EXAMPLE l7 Condensation of l-benzylidene-3-ethoxy-lH-isoindole and pentylammonium chloride affords l-benzylidene-3-(pentylamino) IH-isoindole (1: X-l-X' CHC H Y NQ"Q', Q" (CH LCH Q Z Z H) hydrochloride.

EXAMPLE 18 Condensation of 3-ethoxy'1H-isoindo1e and pchlorobenzylamine affords 3-(p-chlorobenzylamino)- lH-isoindole (1: X X Z Z H. l NQQ', Q

CH,C,H Cl-p, Q'

EXAMPLE 2| Condensation of 3-ethoxy-lH-isoindole and phydroxybenzylamine affords 3-(p-hydroxyben- EXAMPLE 22 Condensation of 3-ethoxy-1H-isoindole and pmethoxybenzylamine affords 3-(p-rnethoxybenzylamino)-lH-isoindole (1:X X' Z Z' H, Y NQQ', Q CH CJLOCHfP. Q' H).

EXAMPLE 23 A mixture of 3-ethoxy-lH-isoindole (9.0 g.), 3,4,5- trimethoxybenzylamine hydrochloride (13.0 g.) and methanol ml.) was heated under reflux (for 5 hr.) under nitrogen. The mixture was stripped of solvent. Recrystallization of the residue (14.3 g., m.p. 227228C.) from isopropyl alcohol gave 3-[(3.4,5- trimethoxybenzyl)amino]-lH-isoindole (1: X X Z Z H, Y NQQ'. Q CH,C,H,(OCH,),-3,4,5, Q H) hydrochloride (8.1 g., m.p. 227228C.).

EXAMPLE 24 Condensation of 3-ethoxy-1H-isoindole and p-(benzyloxy)benzy1amine hydrochloride affords 3-[p-(benzy1oxy)benzylamino]-1H-isoindole (l: X X Z Z H, Y NQQ', Q CH,C.H.OCH,C.H;-p. Q H) hydrochloride.

15 EXAMPLE 2s Condensation of 3-ethoxy-lH-isoindole and p-(methylthio)benzylamine hydrochloride affords 3-[p (methylthio)benzylamino]-lH-isoindole (l: X X Z z' H, Y N. 0 CH c.,H,scH,- Q H) hydrochloride.

EXAMPLE 26 Condensation of 3-ethoxy-l H-isoindole and p (dimethylamino)benzylamine hydrochloride affords 3-[p- (dimethylamino)-benzyl]-l H-isoindole (l: X X Z Z H, Y NQQ, Q CH,C H N(CH -p, O H) hydrochloride.

EXAMPLE 27 EXAMPLE 28 Condensation of 3-ethoxy-lH-isoindole and pnitrobenzylamine affords 3Hp-nitrobenzylamino)-lH isoindole (l: X X Z Z H, Y N00, 0 cH,c,H,N0,- Q H).

EXAMPLE 29 Condensation of 3-ethoxy-1H-isoindole and p-sulfamoylbenzylamine affords 3-(p-sulfamoylbenzylamino)-lH-isoindole (l: X X Z Z H, Y N00. 0 CHzC H SO NH1-P' Q H).

EXAMPLE 30 In a manner similar to that of Example 9, condensation of I-benzylidene-3-ethoxy-lH-isoindole (24.9 g.) and B-(diethylamino)ethylamine (30 ml.) and treatment of the resulting product with hydrochloric acid afforded l-benzylidene-3- [2-(diethylamino)ethyl]- amino}- l H-isoindole (l: X+X' CHC H Y NQ"Q, Q" CH,CH,N(C,H Q Z Z H) dihydrochloride (l8.l g., m.p. 202204C. with decomposition).

EXAMPLE 3l Condensation of l-benzylidene-3-ethoxy-lH-isoindole and dimethylammonium chloride affords l-benzylidene-3-(dimethylamino)-lH-isoindole (l: X+X' a s Y NQ"Q'. Q" Q CH3, Z Z H) hydrochloride.

EXAMPLE 32 Condensation of l-benzylidene-3-ethoxy-lH-isoindole and dibutylammonium chloride affords l-benzylidene-3-(dibutylamino)-lH-isoindole (l: X+X' s s, Y Q"Q', Q" Q (CH hCH Z Z H) hydrochloride.

EXAMPLE 33 A mixture of l-benzylidene-3-ethoxy-lH-isoindole (24.9 g.) and pyrrolidine (40 ml.) was heated at reflux 16 overnight. The resulting solid was washed with ether, affording l-benzylidene-3-( l-pyrrolidinyl)- l H-isoindole (I: X+X' CHC H Y NQ"Q, Q"+Q' N(CH CH z z' H) (I9.7 g., m.p. 212-213c.).

EXAMPLE 34 A mixture of 3-ethoxy-l H-isoindole (22.l g.), hydrazine (97%, 17.8 g.) and absolute ethanol ml.) was heated under reflux (for 2.5 hr.). The mixture was stripped of ethanol and excess hydrazine and the residue was triturated with Skellysolve A. The resulting solid (17.5 g., m.p. 139l4lC.) was recrystallized from acetonitrile, affording 3-hydrazino-lH-isoindole (l: X =X' =Z=Z'=H, Y =NQQ'.Q=NH ,Q'=H) (13.0 g., m.p. l45l46C. with decomposition).

EXAMPLE 35 Condensation of l-methyl-3-ethoxyl H-isoindole and hydrazine affords l-methyl-3-hydrazino-lH-isoindole (I: X=CH X=Z=Z=H,Y =NQQ'.Q= NH,, O H).

EXAMPLE 36 Condensation of l-butyl-3-ethoxy-lH-isoindole and hydrazine affords l-butyl-3-hydrazino-lH-isoindole (l: X (CH CH X Z Z H, Y NQQ, Q NH Q H).

EXAMPLE 37 Condensation of l-phenyl-3-ethoxy-lH-isoindole and hydrazine affords l-phenyl-3-hydrazino-lH-isoindole (I: X C H X Z Z H, Y NQQ', Q NH Q H).

EXAMPLE 38 Condensation of l-benzyl-3-ethoxy-l H-isoindole and hydrazine affords l-benzyl-3-hydrazino-lH-isoindole (l: X C H CH X Z Z H, Y NQQ', Q NH 0' H).

EXAMPLE 39 EXAMPLE 4O Condensation of 3-ethoxy-5-chloro-lH-isoindole (lil: X" X Z H, Q C,H Z Cl) and hydrazine affords 3-hydrazinoS-chloro-lH-isoindole (l: X X'=Z' =H, Y =NQQ,Q=NH,.Q'=H,Z=CI).

EXAMPLE 41 Condensation of 3-ethoxy-5-hydroxy-lH-isoindole (lll: X" X Z H, Q' C H Z HO) and by drazine affords 3-hydrazino-5-hydroxy-ll-l-isoindole (l: X =X'=Z=H, Y=NQQ'.O=NH,,Q=H,Z= HO).

EXAMPLE 42 EXAMPLE 43 Condensation of 3-ethoxy-5,6-dimethoxy-lH-isoindole (lll: X" X H, C H,,, Z Z' CH O) and hydrazine affords 3-hydrazino-5,o-dimethoxy-lH- isoindole (l: X X H, Y N00, 0 NH 0 H, Z Z' CH O).

EXAMPLE 44 Condensation of 3-ethoxy-5,6-methylenedioxy-lH- isoindole (Ill: X" X H, Q' C,H,,, Z+Z' OCH O) and hydrazine affords 3-hydrazino-5,6-methylenedioxy- 1 H-isoindole (l: x x' H, Y N00. 0 NH 0' H, 2+2 OCH,O).

EXAMPLE 45 In a manner similar to that of Example 59, condensation of l-benzylidene-3-ethoxy-lH-isoindole-(24.9 g.) and hydrazine (95%, I42 g.) gave a solid (18.7 g., m.p. 1 l7l20C.), which was recrystallized from benzene, affording l-benzylidene-3-hydrazino-lH-isoindole (l: X+X =CHC H Y N00, 0 NH,, O Z Z H) (9.0 g., m.p. l75I76C.).

EXAMPLE 46 Condensation of 3-ethoxy-1H-isoindole and hydroxylamine hydrochloride affords 3-hydroxylamino-1H- isoindole (l: X =X' Z Z =H, Y =NQQ', Q =OH, Q H) hydrochloride.

EXAMPLE 47 Condensation of 3-hydrazino-lH-isoindole and formaldehyde affords 3-(2-methylenehydrazino)-lH-isoindole (l: X =X' =Z=Z' H, Y NHN=CRR', R=R H).

EXAMPLE 48 Condensation of 3-hydrazino-lH-isoindole and acetaldehyde affords 3-(2-ethylidenehydrazino)-lH-isoindole (I: X X Z Z H, Y NHN=CRR, R CH R H).

EXAMPLE 49 Condensation of 3-hydrazino-lH-isoindole and isobutyraldehyde affords 3-(2-isobutylidenehydrazino)- lH-isoindole (I: X X Z Z H, Y NHN=CRR', R CH(CH:;)2, R H).

EXAMPLE 50 Condensation of 3hydrazino-lH-isoindole and pivaldehyde affords 3-[2-(tert-butylmethylene)hydrazino]-lH-isoindole (l: X X Z Z H, Y NHN=CRR', R C(CH R H).

EXAMPLE 51 Condensation of 3-hydrazino-lH-isoindole and tiglaldehyde affords 3-[2-(2,3-dimethylallylidenc)hydrazinol-lH-isoindole (l: X X Z Z H, Y NHN=CRR, R C(CH )=CHCH R H).

EXAMPLE 52 Condensation of 3-hydrazino-lH-isoindole and cyclopentanecarboxaldehyde affords 3-[2-(cyclopentylmethylene)-hydrazino]-lH-isoindole (I: X X Z EXAMPLE 53 Condensation of 3-hydrazino-lH-isoindole and 3- cyclohexenecarboxaldehyde affords 3-[2-(cyclohexenylmethylene)hydrazinol-lH-isoindolc (I: X X Z Z H, Y NHN=CRR, R CHCH CH=CHCH CH R' H).

EXAMPLE 54 Condensation of 3-hydrazinol H-isoindole and benzaldehyde affords 3-(2-benzylidenehydrazino)-lH- EXAMPLE 55 Condensation of 3-hydrazino-lH-isoindole and aphenylpropionaldehyde affords 3-[2-(2-phenyl- EXAMPLE 56 EXAMPLE 57 Condensation of 3-hydrazino-lH-isoindole and pbromobenzaldehyde affords 3-[2(p-bromobenzylidene)hydrazino]-iH-isoindole (I: X X Z Z H, Y NHN=CRR, R C,,H,Br-p, R' H).

EXAMPLE 58 Condensation of 3-hydrazino-lH-isoindole and mhydroxybenzaldehyde affords 3-[2-(m-hydroxybenzylidene )hydrazinol-lH-isoindole (l: X X' Z Z H, Y NHN=CRR', R C H OH-m, R H).

EXAMPLE 59 Condensation of 3-hydrazino-lH-isoindole and ptolualdehyde affords 3-[2-(p-methylbenzylidene)hydrazinol-lH-isoindole (l: X X Z 2' H, Y NHN=CRR', R C H CH -p, R H).

EXAMPLE 60 Condensation of 3-hydrazino-lH-isoindole and syringaldehyde affords 3-[2-(3,5-dimethoxy-4-hydroxybenzylidene)hydrazino]-lH-isoindole (l: X X Z Z H, Y NHN=CRR', R =C H=OH-4-(OCH -3,5, R

EXAMPLE 61 Condensation of 3-hydrazino-lH-isoindole and p- (ethylthio)benzaldehyde affords 3-{2-[p-(ethylthio)- benzylidene]hydrazino}-lH-isoindole (l: X X' Z Z H, Y NHN=CRR, R C H SC H -p, R H).

EXAMPLE 62 Condensation of 3-hydrazino-lH-isoindole and p (dimethylamino)benzaldehyde affords 3-{2-[p-(dimethylamino)benzylidene]-hydrazino}-lH-isoindole (l: X

Condensation of 3-hydrazino lH-isoindole and p-[Z- (diethylamino)ethoxylhenzaldehyde affords 3- 2-{p- (2-(diethylamino)ethoxy]bcnzylidene}hydrazino lH isoindole (l: X X Z Z H, Y NHN=CRR', R C H OCH CH N(C H -p. R H).

EXAMPLE 64 Condensation of 3-hydrazino-l H-isoindole and pnitrobenzaldehyde affords 3-[2-(p-nitrobenzylidene)- hydrazino1-ll-l-isoindole (l: X X Z Z H, Y NHN=CRR, R C H NO -p, R H),

EXAMPLE 65 Condensation of 3-hydrazinol l-l-isoindole and psulfamoylbenzaldehyde affords 3-[2-(p-sulfamoylbenzylidene)-hydrazino]-lH-isoindole (l: X X Z Z H, Y NHN=CRR', R C H SO NH -p, R H).

EXAMPLE 66 A mixture of 3hydrazino-lH-isoindole g.), acetone (530 ml.) and sulfuric acid l0 g.) was stirred (for l hr. at 15C. The resulting solid was collected by filtration, washed with ether and dried, affording 3-(2- isopropylidenehydrazino)- l H-isoindole (l: X X Z Z H, Y NHN=CRR, R R CH sulfate (l9.5 g., m.p. l38-i40C.).

EXAMPLE 67 Condensation of 3-hydrazino-lH-isoindole and methyl isopropyl ketone affords 3-[2-(i,2-dimethylpropylidene)hydrazino]-l H-isoindole (l: X X Z Z H, Y NHN=CRR, R CH;,, R CH(CH;,),).

EXAMPLE 68 Condensation of 3-hydrazino-1H-isoindole and cyclohexanone affords 3-(2-cyclohexylidenehydrazino)- lH-isoindole (l: X X Z Z H, Y NHN=CRR', R+R C(CH LCH EXAMPLE 69 Condensation of l-methyl-3-hydrazino-1H-isoindole and acetone affords l-methyl-3-(2-isopropylidenehydrazino)-lH-isoindole (I: X CH;,, X Z Z' H, Y NHN=CRR'. R R CH;,).

EXAMPLE 70 Condensation of l -butyl-3-hydrazino-1H-isoindole and acetone affords l-butyl-3-(2-isorpopylidenehydrazino)-lH-isoindole (l: X (CH -,CH;,, X Z Z H, Y NHN=CRR', R R CH EXAMPLE 71 Condensation of l-phenyl-3-hydrazino-lH-isoindole and acetone affords l-phenyl-3-(2-isopropylidenehydrazino)-lH-isoindole (l: X C H X Z Z H, Y NHN=CRR, R R CH EXAMPLE 72 Condensation of l-benzyl-S-hydrazinol H isoindole and acetone affords l-benzyl-3-(2-isopropylidenehydrazino)-lH-isoindole (l: X C H CH X Z Z H, Y NHN=CRR, R R CH;,).

20 EXAMPLE 73 Condensation of 3-hydrazino-6-methyl-lH-isoindole and acetone affords 3-(Z-isopropylidenehydrazino)-5- methyl-lH-isoindole (l: X X Z H, Y NHN=CRR', R R Z CH EXAMPLE 74 Condensation of B-hydrazino-S-chloro-lH-isoindole and acetone affords 3-(2-isopropylidenehydrazino)-6- chloro-lH-isoindole (l: X X' Z H, Y NHN=CRR, R R CH Z Cl).

EXAMPLE 75 Condensation of 3-hydrazino-5-hydroxy-ll-Hsoindole and acetone affords 3-(2-isopropylidenehydrazino)-6-hydroxy-lH-isoindole (I: X X Z H, Y NHN=CRR, R R CH 2 HO).

EXAMPLE 76 Condensation of 3-hydrazino-5-methoxy-lH-isoindole and acetone affords 3-(2-isopropylidenehydrazino)-6-methoxy-lH-isoindole (l: X X Z H, Y NHN=CRR, R R CH Z CH;,O).

EXAMPLE 77 Condensation of 3-hydrazino-5,o-dimethoxy-1H- isoindole and acetone affords 3-(2-isopropylidenehydrazino)-5,6-dimethoxyl H-isoindole (I: X X H, Y NHN=CRR, R R CH Z Z CH O).

EXAMPLE 78 Condensation of 3-hydrazino-5,o-methylenedioxylH-isoindole and acetone affords 3-( 2-isopropylidenehydrazino)-S ,-methylenedioxyl H-isoindole (l: X X H, Y NHN=CRR, R R =CH 2+2 OCH O).

EXAMPLE 79 EXAMPLE 80 [n a manner similar to that of Example 56, condensation of 3-hydrazino-lH-isoindole (14.7 g.) and transcinnamaldehyde (13.8 g.) and treatment of the resulting product with hydrogen chloride afforded 3-[2-(3- phenylallylidene)hydrazinol-IH-isoindole (l: X X Z Z H, Y NHN==CRR, R CH CHC.,H,, R H) hydrochloride 16.0 g., m.p. 2 l 2-2l4C. with decomposition).

1 claim:

1. l-(X)-l -(X')-3-( Y)-5-(Z)-6-(Z')-l H-lsoindole of the formula I X I wherein:

X is hydrogen or atertiary alkyl of one to four carbon atoms;

X is hydrogen;

Y is N or NHN=CRR';

wherein:

O is amino or hydroxy;

Q is hydrogen or atertiary alkyl of one to four carbon atoms;

R, when taken alone, is hydrogen, alkyl of one to six carbon atoms, alkenyl of two to six carbon atoms, cycloalkyl of three to seven ring atoms and three to ten carbon atoms, cycloalkenyl of five to seven ring atoms and five to ten carbon atoms, phenyl, phenylalkyl of seven to ten carbon atoms or phenylalkenyl of eight to twelve carbon atoms;

R, when taken alone, is hydrogen or atertiary alkyl of one to four carbon atoms; or

R and R, when taken together with C, are cycloalkylidene of five to seven ring atoms and five to ten carbon atoms;

Z and 2', when taken alone, are the same or different and are hydrogen, atertiary alkyl of one to four carbon atoms, halo, hydroxy or atertiary alkoxy of one to four carbon atoms; or

Z and 2, when taken together, are methylenedioxy;

and wherein,

when R is phenyl, phenylalkyl or phenylalkenyl, the benzene ring thereof can be substituted by one to three members selected from the group consisting of halo, hydroxy. atertiary alkyl of one to four carbon atoms, atertiary alkoxy of one to four carbon atoms and phenylalkoxy of seven to ten carbon atoms or by a member selected from the group consisting of atertiary alkylthio of one to four carbon atoms, dialkylamino and B-dialkylaminoethoxy, wherein alkyl of dialkylamino is atertiary alkyl of one to four carbon atoms, nitro and sulfamoyl; or an acid addition salt thereof,

2. l-(X)-l-(X)-3-(Y)-S-(Z)-6-(Z')-lH-lsoindole wherein Y is N00 and Q is amino or an acid addition salt thereof according to claim I.

3. 1-(X)-l-(X)-3-(Y)-5-(Z)-6-(Z')-l H-lsoindole wherein Z and Z' are each hydrogen or an acid addition salt thereof according to claim 2.

4. 3-Hydrazino-lH-isoindole or an acid addition salt thereof according to claim 3.

5. l-(X)-l-(X)3-(Y)-5-(Z)-6-(Z)-IH-lsoindole wherein Y is NHN=CRR' or an acid addition salt thereof according to claim I.

6. l-(X)-l-(X')-3-(Y)-5-(Z)-6-(Z')-lH-lsoindole wherein Z and Z are each hydrogen or an acid addition salt thereof according to claim 5.

7. 3-[2-(3-Phenylallylidene)hydrazino1-1H-isoindole or an acid addition salt thereof according to claim 6.

8. 3-[2-(2-Methyl-3-phenylallylidene)hydrazinollH-isoindole or an acid addition salt thereof according to claim 6.

9. 3-(2-lsopropylidenehydrazino)-lH-isoindole or an acid addition salt thereof according to claim 6.

I l k i 

1. 1-(X)-1-(X'')-3-(Y)-5-NZ)-6-NZ'')-1H-ISOINDOLE OF THE FORMULA
 2. 1-(X)-1-(X'')-3-(Y)-5-(Z)-6-(Z'')-1H-Isoindole wherein Y is NQQ'' and Q is amino or an acid addition salt thereof according to claim
 1. 3. 1-(X)-1-(X'')-3-(Y)-5-(Z)-6-(Z'')-1H-Isoindole wherein Z and Z'' are each hydrogen or an acid addition salt thereof according to claim
 2. 4. 3-Hydrazino-1H-isoindole or an acid addition salt thereof according to claim
 3. 5. 1-(X)-1-(X'')-3-(Y)-5-(Z)-6-(Z'')-1H-Isoindole wherein Y is NHN CRR'' or an acid addition salt thereof according to claim
 1. 6. 1-(X)-1-(X'')-3-(Y)-5-(Z)-6-(Z'')-1H-Isoindole wherein Z and Z'' are each hydrogen or an acid addition salt thereof according to claim
 5. 7. 3-(2-(3-Phenylallylidene)hydrazino)-1H-isoindole or an acid addition salt thereof according to claim
 6. 8. 3-(2-(2-Methyl-3-phenylallylidene)hydrazino)-1H-isoindole or an acid addition salt thereof according to claim
 6. 9. 3-(2-Isopropylidenehydrazino)-1H-isoindole or an acid addition salt thereof according to claim
 6. 